Innovation Days
About
Research
Products
Investors
Careers
Agenda
fr
Press Releases
Our latest news and press releases
stock information
press releases
events and webcasts
Scientific Presentations
Scientific Publications
corporate presentation
Financial Statements
SEC filings
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
All
2022
2021
2020
2019
2018
2017
04
Aug 2022
16:30 E.S.T.
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
Read more
01
Aug 2022
16:30 E.S.T.
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
Read more
28
Jul 2022
16:30 E.S.T.
Cellectis to Report Second Quarter 2022 Financial Results
Read more
30
Jun 2022
05:00 E.S.T.
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence
Read more
28
Jun 2022
16:30 E.S.T.
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors
Read more
28
Jun 2022
16:05 E.S.T.
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022
Read more
1
2
3
Next